Zydus Cadila completes Phase 3 Trial of Saroglitazar Magnesium

02 Aug 2019

Zydus Cadila has completed Phase 3 Clinical Trial in India of Saroglitazar Magnesium for treating Type 2 Diabetes. The trial was a multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of Saroglitazar compared to Pioglitazone 45mg in patients with Type 2 Diabetes Mellitus. The Phase 3 trial enrolled 1140 subjects and studied the patients over a period of 56 weeks.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Related Cadila Healthcare Ltd. Links:

Cadila Healthcare Share Price

486.90 -13.05 (-2.61%) Apr 13, 13:25
1 Year Price Chart
Company Name CMP
Sun Pharma Inds. 628.75
Dr. Reddys Lab 4809.70
Lupin 1035.25
Piramal Enterprises 1690.90
Cadila Healthcare 486.90
View more..
Sensex vs Cadila Healthcare
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323